Related Experiment Video
Updated: Feb 27, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
Oral Insulin Delivery in a Physiologic Context: Review.
11 Oramed Pharmaceuticals, Inc. Jerusalem, Israel.
Journal of Diabetes Science and Technology
|June 28, 2017
Summary
Oral insulin offers a more convenient alternative to injections for diabetes management. This review explores its development, physiological benefits, and potential to improve glucose control while reducing hypoglycemia risks.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Insulin is crucial for diabetes treatment but injectable formulations limit its use.
- Oral insulin aims to improve convenience and therapeutic outcomes through direct liver delivery.
- Mimicking natural insulin pathways may offer unique metabolic benefits.
Purpose of the Study:
- To review oral insulin in a physiological context.
- To report on the latest advancements in oral insulin development.
- To highlight the potential advantages of oral insulin over traditional injectable forms.
Main Methods:
- Literature review of physiological insulin delivery.
- Analysis of recent preclinical and clinical studies on oral insulin formulations.
- Examination of pharmacokinetic and pharmacodynamic data.
Main Results:
- Oral insulin's direct portal delivery may enhance hepatic insulin sensitivity.
- Potential to reduce systemic hyperinsulinemia and associated hypoglycemia.
- Development is progressing towards late-stage trials.
Conclusions:
- Oral insulin represents a significant advancement in diabetes therapy.
- Its physiological delivery mechanism offers potential therapeutic advantages.
- Further development is crucial for widespread clinical adoption.
More Related Videos
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
872
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
872
01:16Insulin: Dosing Regimen and Adverse Effects
948
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
948
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.8K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.8K
01:24Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
01:22Diabetes Mellitus: Overview and Type I Subtype
5.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.7K